• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结核病:德国的疾病负担。

Tuberculosis: cost of illness in Germany.

机构信息

Dept of Pneumology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.

出版信息

Eur Respir J. 2012 Jul;40(1):143-51. doi: 10.1183/09031936.00204611. Epub 2012 Jan 20.

DOI:10.1183/09031936.00204611
PMID:22267754
Abstract

4,444 new cases of tuberculosis (TB) were reported in Germany in 2009; of those, the proportion of multidrug-resistant (MDR)-TB cases increased to 2.1% (63 cases). On the basis of the therapy guidelines of the German Central Committee against Tuberculosis and the new World Health Organization guidelines, this study estimates the mean direct outpatient and combined in- and outpatient costs of TB, together with other attributable costs of the disease on the basis of the most recent German official health statistics and scientific literature. According to this, the mean outpatient costs (rounded) per case were €1,197 (adults) and €1,006 (children) for standard therapy, but €36,543 for treatment of MDR-TB. The mean combined in-patient/outpatient costs were €7,364 (adults) and €7,300 (children), respectively; the combined costs for treatment of MDR-TB amounted to €52,259. Including MDR-TB cases the mean costs of treatment per TB case were €7,931. These are joined by the mean costs due to loss of productivity (€2,313), costs per case for rehabilitation (€74) and contact tracing (€922), adding up to €11,240. When considering the probability of increasing numbers of MDR-TB cases in the near future, TB is still a disease of significant economic impact in Germany.

摘要

2009 年德国报告了 4444 例新的肺结核(TB)病例;其中,耐多药(MDR)-TB 病例的比例增加到 2.1%(63 例)。基于德国中央结核病防治委员会和新的世界卫生组织指南的治疗指南,本研究根据最新的德国官方卫生统计数据和科学文献,估计了 TB 的平均直接门诊和联合门诊和住院费用,以及该疾病的其他相关费用。根据这一估计,标准治疗的平均门诊费用(四舍五入)为每例 1197 欧元(成人)和 1006 欧元(儿童),但 MDR-TB 的治疗费用为 36543 欧元。平均联合门诊和住院费用分别为 7364 欧元(成人)和 7300 欧元(儿童);MDR-TB 的联合治疗费用为 52259 欧元。包括 MDR-TB 病例在内,每例 TB 的治疗平均费用为 7931 欧元。这些费用加上因生产力损失而产生的平均费用(2313 欧元)、每例康复费用(74 欧元)和接触者追踪费用(922 欧元),总计为 11240 欧元。考虑到未来 MDR-TB 病例数量可能增加,TB 在德国仍然是一种具有重大经济影响的疾病。

相似文献

1
Tuberculosis: cost of illness in Germany.结核病:德国的疾病负担。
Eur Respir J. 2012 Jul;40(1):143-51. doi: 10.1183/09031936.00204611. Epub 2012 Jan 20.
2
Cost of multi drug resistance tuberculosis in Germany.德国耐多药结核病的成本。
Respir Med. 2014 Nov;108(11):1677-87. doi: 10.1016/j.rmed.2014.09.021. Epub 2014 Oct 15.
3
Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador.厄瓜多尔耐多药结核病患者及其家庭的费用。
Int J Tuberc Lung Dis. 2010 Oct;14(10):1316-22.
4
Cost analysis of different types of tuberculosis patient at tuberculosis centers in Thailand.泰国结核病防治中心不同类型结核病患者的成本分析。
Southeast Asian J Trop Med Public Health. 2002 Jun;33(2):321-30.
5
Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.南非耐多药结核病住院治疗费用。
Trop Med Int Health. 2013 Jan;18(1):109-16. doi: 10.1111/tmi.12018. Epub 2012 Nov 21.
6
Cost of multidrug resistant tuberculosis in Germany-An update.德国耐多药结核病的成本:更新。
Int J Infect Dis. 2021 Feb;103:102-109. doi: 10.1016/j.ijid.2020.10.084. Epub 2020 Nov 3.
7
Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Estonia 和俄罗斯的耐多药结核病治疗的成本和成本效益。
Eur Respir J. 2012 Jul;40(1):133-42. doi: 10.1183/09031936.00169411. Epub 2012 Feb 23.
8
Cost of treatment for multidrug-resistant tuberculosis in South Korea.韩国耐多药结核病的治疗费用。
Respirology. 2006 Nov;11(6):793-8. doi: 10.1111/j.1440-1843.2006.00948.x.
9
[The cost of treatment in new case and multidrug resistant case in pulmonary tuberculosis].[肺结核新发病例和耐多药病例的治疗成本]
Tuberk Toraks. 2003;51(4):410-5.
10
Cost of illness of non-multidrug-resistant tuberculosis in Germany: an update.德国非耐多药结核病的疾病成本:最新情况
ERJ Open Res. 2020 Oct 26;6(4). doi: 10.1183/23120541.00329-2020. eCollection 2020 Oct.

引用本文的文献

1
HIV and body mass index are associated with prolonged corrected QT interval among people with drug-resistant tuberculosis on bedaquiline-containing regimen in Uganda.在乌干达接受含贝达喹啉方案治疗的耐多药结核病患者中,HIV和体重指数与校正QT间期延长有关。
IJID Reg. 2024 Sep 10;13:100438. doi: 10.1016/j.ijregi.2024.100438. eCollection 2024 Dec.
2
Ending tuberculosis: the cost of missing the World Health Organization target in a low-incidence country.终结结核病:在低发病国家错过世界卫生组织目标的代价。
Ir J Med Sci. 2023 Aug;192(4):1547-1553. doi: 10.1007/s11845-022-03150-3. Epub 2022 Sep 19.
3
Latent Tuberculosis Infection among Health Workers in Germany-A Retrospective Study on Progression Risk and Use of Preventive Therapy.
德国卫生工作者中的潜伏性结核病感染——进展风险和预防性治疗使用的回顾性研究。
Int J Environ Res Public Health. 2021 Jul 1;18(13):7053. doi: 10.3390/ijerph18137053.
4
Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas.对申请美国非移民工作签证者进行结核病筛查的成本效益分析。
Pneumonia (Nathan). 2020 Dec 25;12(1):15. doi: 10.1186/s41479-020-00078-z.
5
Cost of illness of non-multidrug-resistant tuberculosis in Germany: an update.德国非耐多药结核病的疾病成本:最新情况
ERJ Open Res. 2020 Oct 26;6(4). doi: 10.1183/23120541.00329-2020. eCollection 2020 Oct.
6
Incidence of Tuberculosis in Systemic Necrotizing Vasculitides: A Population-Based Study From an Intermediate-Burden Country.系统性坏死性血管炎中结核病的发病率:一项来自中等负担国家的基于人群的研究。
Front Med (Lausanne). 2020 Oct 22;7:550004. doi: 10.3389/fmed.2020.550004. eCollection 2020.
7
Cost-effectiveness of targeted screening for active pulmonary tuberculosis among asylum-seekers: A modelling study with screening data from a German federal state (2002-2015).针对寻求庇护者中活动性肺结核的目标筛查的成本效益:来自德国联邦州(2002-2015 年)筛查数据的建模研究。
PLoS One. 2020 Nov 5;15(11):e0241852. doi: 10.1371/journal.pone.0241852. eCollection 2020.
8
Hospital inpatient care utilization among patients with tuberculosis, Republic of Ireland, 2015-2018.2015-2018 年爱尔兰共和国结核病患者的住院医疗利用情况。
PLoS One. 2020 Aug 27;15(8):e0238142. doi: 10.1371/journal.pone.0238142. eCollection 2020.
9
Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation.重度结核病及其后遗症的管理:从重症监护到手术与康复
J Bras Pneumol. 2019 Apr 25;45(2):e20180324. doi: 10.1590/1806-3713/e20180324.
10
Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study.耐多药结核病患者早期使用贝达喹啉和地拉马尼的障碍与促进因素:一项混合方法研究
Public Health Action. 2019 Mar 21;9(1):32-41. doi: 10.5588/pha.18.0078.